FASN and glioblastoma: Some groups have narrowed their analyses to a single protein biomarker, such as Hsp70 [55], syndecan-1 [54], or fatty acid synthase [57]; however, it is unlikely that a single biomarker will adequately capture the intratumoral heterogeneity of GBM, individual differences between patients, and variable responses to treatment.